Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.
Vericel Corporation filed a report stating it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for January 14, 2026, at 11:15 a.m. Pacific Time. In connection with the conference, the company issued a January 13, 2026 press release that provides preliminary, unaudited financial information for full-year 2025.
The press release includes estimates of Vericel’s 2025 revenue, net income, gross margin percentage, adjusted EBITDA margin, and its cash and investments balance as of December 31, 2025, along with additional financial and business updates. The company emphasizes that these figures are preliminary, have not been audited or reviewed by PricewaterhouseCoopers LLP, and may change, so stockholders are cautioned not to place undue reliance on them.
Vericel Corp’s Chief Operating Officer Michael Halpin reported option exercises and share sales. On 01/07/2026 he exercised 10,000 stock options at $16.66 per share, receiving 10,000 shares of common stock. He then sold 10,000 common shares at $40.48 per share in an automatic transaction under a Rule 10b5-1 trading plan adopted on November 19, 2024.
After these transactions, Halpin directly owned 16,080 shares of Vericel common stock and 46,250 stock options. The reported options were originally part of a grant representing the right to purchase 76,250 shares that vested in equal quarterly installments starting on May 6, 2019, contingent on continued service to the company.
This Form 144 notice discloses a planned sale of 10,000 shares of common stock in the issuer by Michael Halpin. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of 404,832.95.
The 10,000 shares were acquired on 01/07/2026 via a cash exercise of a stock option that was granted on 02/06/2019 by the issuer. The notice also reports that, in the past three months, Halpin sold additional common shares: 7,358 shares on 11/06/2025 for gross proceeds of 297,774.58, and 2,642 shares on 11/11/2025 for gross proceeds of 106,759.79.
By signing the notice, the selling holder represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Vericel Corporation’s chief human resources officer reported the vesting of equity awards on July 22, 2025. Restricted stock units granted on July 22, 2024 converted into 2,625 shares of common stock, with the issuer withholding 771 shares to satisfy tax obligations at a fair market value of $37.98 per share. After these transactions, the officer directly owns 1,854 common shares and 7,875 restricted stock units, each RSU representing the right to receive one Vericel share. The remaining RSUs from this grant are scheduled to vest in annual installments on July 22, 2026, July 22, 2027, and July 22, 2028.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin on 11/11/2025. He exercised a stock option for 2,642 shares at $16.66 (code M) and sold 2,642 shares at $40.41 (code S). The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, he directly owned 15,932 shares. Derivative holdings included 56,250 stock options. The footnotes note prior shares acquired under the 2015 Employee Stock Purchase Plan and the vesting schedule of the option grant.
Vericel (VCEL) reported an insider transaction by a director on 11/10/2025. The director exercised 7,000 stock options at an exercise price of $2.63 (code M) and sold 7,000 shares at an average price of $38.59 (code S) under a Rule 10b5-1 trading plan adopted on March 11, 2024.
Following these transactions, the director reported 15,100 shares beneficially owned directly and 10,500 options remaining beneficially owned. The options exercised were part of a grant from May 3, 2017 that vested in equal monthly installments over one year contingent on continued service.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin. On 11/06/2025, he exercised 7,358 stock options at $16.66 per share and sold 7,358 common shares at $40.47, with the sale executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, Halpin directly beneficially owned 15,932 common shares. His remaining derivative holdings included 58,892 stock options. Footnotes note prior shares acquired under the company’s 2015 Employee Stock Purchase Plan.
Vericel (VCEL) filed its Q3 2025 Form 10‑Q, reporting total revenue of $67.503 million, up 16.6% year over year, and net income of $5.074 million versus a loss in the prior year period. Gross profit was $49.585 million as MACI led growth.
Product mix shifted: MACI revenue rose to $55.662 million (up 24.6%), NexoBrid increased to $1.466 million, while Epicel declined to $10.375 million. For the nine months, revenue reached $183.341 million (up 13.3%) with a narrower net loss of $6.725 million.
Balance sheet and liquidity: Cash and cash equivalents were $100.403 million, with investments of $84.641 million. The company has a $150.0 million undrawn revolving credit facility and total shareholders’ equity of $321.858 million. Operating lease liabilities totaled $98.006 million current and long‑term combined.
Operational updates: MACI Arthro remained in market following the 2024 sBLA approval enabling arthroscopic delivery. Management highlighted Burlington, MA facility progress and continued U.S. commercialization of NexoBrid under the MediWound supply agreements.
Vericel Corporation furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information in this report and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. Additional materials include the Inline XBRL cover page as Exhibit 104.
Jonathan Siegal, Principal Accounting Officer of Vericel Corporation (VCEL), reported securities transactions dated 09/30/2025. He received 938 shares upon vesting of restricted stock units originally granted on 09/30/2021, with a stated fair market value of $31.47 per share. To satisfy tax withholding on the vesting, 370 shares were withheld by the issuer at that same $31.47 value. The filing shows 2,440 shares beneficially owned after the RSU vesting and 2,070 shares beneficially owned following the withholding transaction. The report was signed by an attorney-in-fact on behalf of Mr. Siegal on 10/02/2025.